// App-Quantinova.ai

10742 : Arterial Access Site and Outcomes in Patients Undergoing Percutaneous Coronary Intervention With and Without Vorapaxar

Researchers

Presenter

  • Kenneth Mahaffey

Principal Investigators

  • Pierluigi Tricoci

  • Claes Held

  • Philip Aylward

  • SAHMRI

  • Paul W Armstrong

  • Sunil Rao

  • Harvey White

  • Mohua Podder

  • David Moliterno

  • Robert Harrington

  • Edmond Chen

  • John Strony

  • Frans Van de Werf

  • Khaled M Ziada

Medical Centers

  • Quebec Heart and Lung Inst, Quebec, QC, Canada

  • Gill Heart Inst and Univ of Kentucky, Lexington, KY

  • Duke Univ Medical Ctr/Duke Clinical Res Inst, Durham, NC

  • Gill Heart Inst and Univ of Kentucky, Lexington, KY

  • Leuven Catholic Univ, Leuven, Belgium

  • Flinders University Medical Centre, Adelaide, Australia

  • Univ of Alberta., Canadian VIGOUR Ctr , Edmonton, AB, Canada

  • Uppsala Clinical Res Ctr, Uppsala Univ, Uppsala, Sweden

  • Green Lane Cardiovascular Service, Auckland, New Zealand

Locations

  • Canada

  • Australia

  • United States

  • Belgium

  • Sweden

  • New Zealand

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute Coronary Syndromes

  • Myocardial infarction

  • Coronary Artery Disease

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Vorapaxar

  • Evithrom

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved